BioSig Technologies Inc., a medical device company developing a proprietary biomedical signal processing technology platform designed to address an unmet need for the electrophysiology (EP) marketplace, has hired Manasi Patwardhan as director of Strategic Planning.  
 
Patwardhan brings to BioSig over 18 years of program management and product development experience with several Fortune 500 companies in the medical technology, pharma and healthcare verticals. A biomedical engineer by training, Patwardhan’s core competencies span manufacturing and vendor management, systems engineering, cross-functional team leadership and process improvements. Most recently, Patwardhan was in a technical program management role at Verily Life Sciences LLC, an Alphabet Inc. company, a role, in which she led hardware development for a class III therapy technology program as well as supply-chain and vendor management. Prior to that, Patwardhan was employed by Boston Scientific - Neuromodulation, where she was responsible for delivering a range of technology and product development programs, including commercially launched products in the Spinal Cord Stimulation portfolio as well as a connected health eco system. Earlier in her career Patwardhan was with Medtronic Diabetes, where she led product development efforts for class II therapy, diagnostic and combination products. Her work involved the delivery of engineering solutions from cross-functional teams comprising human factors, marketing, industrial design, hardware and software design and third-party vendors.

Patwardhan earned a master of science degree in biomedical engineering from the University of Southern California - Los Angeles and a bachelor of engineering, chemical engineering degree from the University of Pune, India.
 
“Manasi impressed us with her accomplishments in strategic delivery of complex engineering projects. Her expertise in successfully navigating the fast-paced product development environment will be of significant value to our growing operations,” stated Kenneth L. Londoner, founder, chairman and CEO of BioSig Technologies Inc.
 
BioSig recently announced that it has been added to the Russell 3000 Index and was allowed 33 patent claims covering its PURE EP System. In the first half of 2019 BioSig successfully conducted first patient cases using its PURE EP System at the Texas Cardiac Arrhythmia Institute in Austin, Greenville Memorial Hospital in Greenville, S.C., and Indiana University School of Medicine. These initial experiences suggested improved cardiac signal detection and fidelity.
 
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. Led by a management team and a veteran Board of Directors, BioSig Technologies is preparing to commercialize its PURE EP System. The technology has been developed to address an unmet need in a large and growing market.

The Company’s first product, PURE EP System, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. BioSig’s ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and received U.S. Food and Drug Administration 510(k) clearance for the PURE EP System in August 2018.